drugset / Trial / NCT01648634
Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
Phase 3
Completed
51 enrolled
Assistance Publique - Hôpitaux de Paris
Association Française contre les Myopathies (AFM), Paris · collabURC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The objective is to determine whether nebivolol, a beta-blockade drug, can prevent the development of heart disease in patients with Duchenne muscular dystrophy aged 10 to 15 year-old.
Timeline
- Start
- 2012-02-13
- Primary completion
- 2021-07-20
- Completion
- 2021-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nebivolol | Other / unclassified | 5 mg | — |
| Subject | Nebivolol | Other / unclassified | 7.5 mg | — |